Effect modification by contextual factors of urate-lowering therapy on serum urate in people with gout: A systematic review with meta-regression analysis

被引:0
|
作者
te Kampe, Ritch [1 ,2 ,3 ]
Nielsen, Sabrina Mai [4 ,5 ]
Hotea, Ioana [6 ]
van Durme, Caroline [1 ,7 ]
Christensen, Robin [4 ,5 ]
Boonen, Annelies [1 ,2 ]
机构
[1] Maastricht Univ Med Ctr, Div Rheumatol, Dept Internal Med, POB 5800, NL-6202 AZ Maastricht, Netherlands
[2] Maastricht Univ, Care & Publ Hlth Res Inst CAPHRI, Maastricht, Netherlands
[3] VieCuri Med Ctr, Dept Rheumatol, Venlo, Netherlands
[4] Bispebjerg & Frederiksberg Hosp, Sect Biostat & Evidence Based Res, Copenhagen, Denmark
[5] Univ Southern Denmark, Odense Univ Hosp, Dept Clin Res, Res Unit Rheumatol, Odense, Denmark
[6] Univ Med & Pharm, Dept Rheumatol, Cluj Napoca, Romania
[7] Ctr Hosp Chretien, Liege, Belgium
关键词
Gout; Urate-lowering therapy; Contextual factors; Renal function; Effect modification; DOUBLE-BLIND; INADEQUATE RESPONSE; CLINICAL-TRIALS; ALLOPURINOL; FEBUXOSTAT; MULTICENTER; MANAGEMENT; LESINURAD; OUTCOMES; PLACEBO;
D O I
10.1016/j.semarthrit.2022.152049
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To synthesize evidence of the effect of contextual factors (CFs) on efficacy of urate-lowering therapy (ULT) on serum urate (SU) as outcome in gout patients. Methods: Randomised controlled trials (RCTs) from (updated) Cochrane reviews were the starting point. RCTs were included if they explored the role of any CF on efficacy of ULT on SU in gout patients. For CFs with sufficient data (i.e. >= 3 trials), a mixed-effects meta-regression analysis was performed with trial and comparison as random effects, whereas specific CFs were modelled as fixed factors. Results: Eight RCTs were included. Effect modification by CFs was explored for age, sex, race, renal function, cardiovascular comorbidity, tophi, thiazide-diuretic use, and previous ULT use. Crude data stratified by renal function were available for four trials (36 randomised comparisons), and suitable for meta-analysis. Pooled estimates revealed that gout patients with a normal, mildly-, or moderately impaired renal function were consistently more likely to achieve SU target with ULT compared to control. Among RCTs comparing ULT to placebo (30 comparisons), effects of ULT on achieving SU target were not statistically different for those with normal (OR:66.87; [11.39-392.75]) compared to mildly (OR:28.54; [5.11-159.46]) and moderately (OR:21.45; [3.20-143.64]) impaired renal function, but seemed lower in those with severely impaired (OR:9.13; [0.96-86.97]) renal function. Data were insufficient to draw conclusions on effect modification by other CFs. Conclusion: Few RCTs report stratified analyses exploring the role of CFs. ULT seemed effective in reaching the SU target in all levels of renal function, though severely impaired renal function appeared to render a slight disadvantage.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] SAFETY OF ALLOPURINOL COMPARED WITH OTHER URATE-LOWERING DRUGS IN PATIENTS WITH GOUT: A SYSTEMATIC LITERATURE REVIEW AND META-ANALYSIS
    Castrejon, I.
    Toledano, E.
    Rosario, M. P.
    Loza, E.
    Perez-Ruiz, F.
    Carmona, L.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 710 - 710
  • [42] Using serum urate as a validated surrogate end point for flares in patients with gout: protocol for a systematic review and meta-regression analysis
    Morillon, Melanie B.
    Stamp, Lisa
    Taylor, William
    Fransen, Jaap
    Dalbeth, Nicola
    Singh, Jasvinder A.
    Christensen, Robin
    Lassere, Marissa
    BMJ OPEN, 2016, 6 (09):
  • [43] Risk of fragility fracture among patients with gout and the effect of urate-lowering therapy
    Sultan, Alyshah Abdul
    Whittle, Rebecca
    Muller, Sara
    Roddy, Edward
    Mallen, Christian D.
    Bucknall, Milica
    Helliwell, Toby
    Hider, Samantha
    Paskins, Zoe
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2018, 190 (19) : E581 - E587
  • [44] Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout
    Perez-Ruiz, F
    Calabozo, M
    Pijoan, J
    Herrero-Beites, AM
    Ruibal, A
    ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2002, 47 (04): : 356 - 360
  • [45] Cardiovascular Disease in Gout and theProtective Effect of Treatments Including Urate-Lowering Therapy
    Gupta, Manik K.
    Singh, Jasvinder A.
    DRUGS, 2019, 79 (05) : 531 - 541
  • [46] Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy
    Manik K. Gupta
    Jasvinder A. Singh
    Drugs, 2019, 79 : 531 - 541
  • [47] Effect of Urate-Lowering Therapy on the Progression of Kidney Function in Patients With Asymptomatic Hyperuricemia: A Systematic Review and Meta-Analysis
    Zhang, Lin
    An, Kang
    Mou, Xingyu
    Zhang, Mei
    Su, Qiaoli
    Li, Shuangqing
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [48] Urate-Lowering Drugs and Muscle Injury: A Systematic Review and Network Meta-Analysis
    Mitsuboshi, Satoru
    Morizumi, Makoto
    Kotake, Kazumasa
    Kaseda, Ryohei
    Narita, Ichiei
    JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 64 (03): : 288 - 299
  • [49] Factors affecting serum urate monitoring among older adults with gout initiating urate-lowering therapy: comment on the article by Kwok et al
    Sheu, Kai-Lun
    Chen, Chun-Chieh
    Chen, Shiuan-Chih
    ARTHRITIS CARE & RESEARCH, 2023, 75 (12) : 2539 - 2540
  • [50] The Effect of Decrease in Serum Urate for the Risk of Gout Flares During Urate-Lowering Therapy Initiation Among Chinese Male Gout Patients: A Prospective Cohort Study
    Pang, Lei
    Xue, Xiaomei
    He, Yuwei
    Wang, Can
    Han, Lin
    Li, Maichao
    Qi, Han
    Li, Changgui
    Lu, Jie
    JOURNAL OF INFLAMMATION RESEARCH, 2023, 16 : 3937 - 3947